<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118958</url>
  </required_header>
  <id_info>
    <org_study_id>KVD824-102</org_study_id>
    <nct_id>NCT05118958</nct_id>
  </id_info>
  <brief_title>Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations</brief_title>
  <official_title>A Multiple Part, Phase 1 Crossover Study in Healthy Subjects to Evaluate the Pharmacokinetic (PK) Profile of KVD824 Following Single and Multiple Doses of Novel KVD824 Modified Release (MR) Formulations Compared to a Reference KVD824 Immediate Release (IR) Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KalVista Pharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KalVista Pharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3 part, phase 1 crossover study in healthy subjects to evaluate the pharmacokinetic&#xD;
      profile of KVD824 following single and multiple doses of novel KVD824 modified-release&#xD;
      formulations compared with a reference KVD824 immediate release formulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 of the study was a single-centre, open-label, non-randomised, 6-period crossover study&#xD;
      designed to investigate the PK and safety of KVD824 MR prototype formulations (with or&#xD;
      without an additional KVD824 IR capsule) compared to a reference KVD824 IR capsule&#xD;
      formulation in healthy male and female subjects. Part 2 was an optional part designed to&#xD;
      investigate the PK and safety of a selected KVD824 MR prototype tablet formulation (with or&#xD;
      without an additional KVD824 IR capsule) in healthy male and female subjects in both the fed&#xD;
      and fasted state. Note: this Part was not conducted as sufficient information on food effect&#xD;
      was collected in the other Parts of the study.&#xD;
&#xD;
      Part 3 was a single-centre, randomised, double-blind, placebo-controlled, multiple dose group&#xD;
      study to investigate the PK and safety of a selected KVD824 MR prototype tablet formulation&#xD;
      (with or without an additional KVD824 IR capsule) in healthy male and female subjects. Part 3&#xD;
      started following completion of Part 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 19, 2020</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Initial open-label crossover (Part 1) followed by double-blind, randomised, placebo-controlled part (Part 3).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics - Tlag</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Time prior to the first measurable concentration after single and multiple doses of KVD824</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Tmax</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Time of maximum observed concentration after single and multiple doses of KVD824 with and without food</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Cmax</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Maximum observed concentration after single and multiple doses of KVD824 with and without food</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Cmax/Dose</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Maximum observed concentration divided by dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - C12</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Plasma concentration observed at time 12 h after single and multiple doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - C24</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Plasma concentration observed at time 24 h after single and multiple doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Ctrough</measure>
    <time_frame>Days 2-14</time_frame>
    <description>Concentration prior to the morning dose on Days 2-14 and prior to the evening dose on Days 2-13</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Cmin</measure>
    <time_frame>Days 2-14</time_frame>
    <description>Minimum observed concentration during the dosing interval (between dose time and dose time plus tau) after single and multiple doses of KVD824 with and without food</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Cavg</measure>
    <time_frame>Days 2-14</time_frame>
    <description>Average concentration (AUC(0-tau)/tau)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUC(0-12)</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Area under the curve from time 0 to 12 hours post-dose after single and multiple doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUC(0-12)/Dose</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Area under the curve from time 0 to 12 hours post-dose divided by dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUC(0-24)</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Area under the curve from time 0 to 24 hours post-dose after single and multiple doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUC(0-24)/Dose</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Area under the curve from time 0 to 24 hours post-dose divided by dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUC(0-last)</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Area under the curve from time 0 to the time of last measurable concentration after single and multiple doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUC(0-last)/Dose</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Area under the curve from time 0 to the time of last measurable concentration divided by dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUC(0-tau)</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Area under the curve for the defined interval between doses (tau)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUC(0-inf)</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Area under the curve from time 0 extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUC(0-inf)/D</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Area under the curve from time 0 extrapolated to infinity divided by dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUCextrap</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - T1/2</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Terminal elimination half-life after single and multiple doses of KVD824 with and without food</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Lambda-z</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>First order rate constant associated with the terminal (log-linear) portion of the curve after single and multiple doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - CL/F</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - CL/Ftau</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Total body clearance calculated using AUC(0-tau) after repeated extravascular administration, where F (fraction of dose bioavailable) is unknown</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Vz/F</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Apparent volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Vz/Flau</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Apparent volume of distribution based on the terminal phase calculated using AUC(0-tau) after extravascular administration where F (fraction of dose bioavailable) is unknown</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Frel Cmax</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Relative bioavailability based on Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Frel AUC(0-12)</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Relative bioavailability based on AUC(0-12)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Frel AUC(0-inf)</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Relative bioavailability based on AUC(0-inf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AR Cmax</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Accumulation ratio based on Cmax repeated dose/Cmax single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Fluctuation</measure>
    <time_frame>Days 1, 10 and 14</time_frame>
    <description>Peak to trough fluctuation (Cmax-Cmin)/Cavg × 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Adverse Events</measure>
    <time_frame>Change from pre-dose to last visit (up to 14 days)</time_frame>
    <description>Number of Subjects with Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Serious Adverse Events</measure>
    <time_frame>Change from pre-dose to last visit (up to 14 days)</time_frame>
    <description>Number of Subjects with Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Laboratory Assessments</measure>
    <time_frame>Throughout the trial to last visit (up to 14 days)</time_frame>
    <description>Number of participants with clinically significant changes in laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Vital Signs</measure>
    <time_frame>Throughout the trial to last visit (up to 14 days)</time_frame>
    <description>Number of participants with clinically significant changes in vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - ECG</measure>
    <time_frame>Throughout the trial to last visit (up to 14 days)</time_frame>
    <description>Number of participants with clinically significant changes in electrocardiogram (ECG) measurements</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>Part 1 - Period 1 - Prototype 1 600 mg (single dose fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg (2 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally in fasted state as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Period 3 - Prototype 2 600 mg (single dose fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg (2 x 300 mg) KVD824 prototype 2 modified-release tablet dosed orally in fasted state as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Period 4 - Prototype 1 900 mg (single dose fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 mg (3 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally in fasted state as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Period 5 - Prototype 1 600 mg and Prototype 3 300 mg (single dose fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg (2 x 300 mg) KVD824 prototype 1 modified-release tablet plus 300 mg (1 x 300 mg) Prototype 3 dosed orally in fasted state as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Period 6 - Prototype 1 900 mg (single dose fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 mg (3 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally in fed state as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 - KVD824 Prototype 1 600 mg (multiple dose fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg (2 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally twice daily in fed state for 13 days with a single dose on day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 - Placebo to KVD824 Prototype 1 600 mg (multiple dose fed)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to 600 mg KVD824 prototype 1 modified-release tablet dosed orally twice daily in fed state for 13 days with a single dose on day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 - KVD824 Prototype 1 900 mg (multiple dose fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 mg (3 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally twice daily in fed state for 13 days with a single dose on day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 - Placebo to KVD824 Prototype 1 900 mg (multiple dose fed)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to 900 mg KVD824 prototype 1 modified-release tablet dosed orally twice daily in fed state for 13 days with a single dose on day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 - KVD824 Prototype 1 900 mg (multiple dose fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 mg (3 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally twice daily in fasted state for 13 days with a single dose on day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 - Placebo to KVD824 Prototype 1 900 mg (multiple dose fasted)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to 900 mg KVD824 prototype 1 modified-release tablet dosed orally twice daily in fasted state for 13 days with a single dose on day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Period 2 - KVD824 IR Capsule 600 mg (single dose fasted)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg (2 x 300 mg) KVD824 immediate release Capsule dosed orally in fasted state as a single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KVD824 Prototype 1 modified-release tablet</intervention_name>
    <description>300 mg modified-release tablet</description>
    <arm_group_label>Part 1 - Period 1 - Prototype 1 600 mg (single dose fasted)</arm_group_label>
    <arm_group_label>Part 1 - Period 4 - Prototype 1 900 mg (single dose fasted)</arm_group_label>
    <arm_group_label>Part 1 - Period 5 - Prototype 1 600 mg and Prototype 3 300 mg (single dose fasted)</arm_group_label>
    <arm_group_label>Part 1 - Period 6 - Prototype 1 900 mg (single dose fed)</arm_group_label>
    <arm_group_label>Part 3 - KVD824 Prototype 1 600 mg (multiple dose fed)</arm_group_label>
    <arm_group_label>Part 3 - KVD824 Prototype 1 900 mg (multiple dose fasted)</arm_group_label>
    <arm_group_label>Part 3 - KVD824 Prototype 1 900 mg (multiple dose fed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KVD824 Prototype 2 modified-release tablet</intervention_name>
    <description>300 mg modified-release tablet</description>
    <arm_group_label>Part 1 - Period 3 - Prototype 2 600 mg (single dose fasted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KVD824 Immediate-Release Capsule</intervention_name>
    <description>300 mg immediate-release capsule</description>
    <arm_group_label>Part 1 - Period 2 - KVD824 IR Capsule 600 mg (single dose fasted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to KVD824 Prototype 1</intervention_name>
    <description>Placebo to 300 mg KVD824 Prototype 1 modified-release tablet</description>
    <arm_group_label>Part 3 - Placebo to KVD824 Prototype 1 600 mg (multiple dose fed)</arm_group_label>
    <arm_group_label>Part 3 - Placebo to KVD824 Prototype 1 900 mg (multiple dose fasted)</arm_group_label>
    <arm_group_label>Part 3 - Placebo to KVD824 Prototype 1 900 mg (multiple dose fed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KVD824 Prototype 3 modified-release tablet</intervention_name>
    <description>300 mg modified-release tablet</description>
    <arm_group_label>Part 1 - Period 5 - Prototype 1 600 mg and Prototype 3 300 mg (single dose fasted)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males or non-pregnant, non-lactating healthy females.&#xD;
&#xD;
          2. Aged 18 to 55 years, inclusive at the time of signing informed consent.&#xD;
&#xD;
          3. Body mass index (BMI) of 18.0 to 32.0 kg/m2 as measured at screening.&#xD;
&#xD;
          4. Must be willing and able to communicate and participate in the whole study.&#xD;
&#xD;
          5. Must provide written informed consent.&#xD;
&#xD;
          6. Must agree to adhere to the contraception requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have received any IMP in a clinical research study within the 90 days&#xD;
             prior to Day 1.&#xD;
&#xD;
          2. Subjects who are study site employees, sponsor employees, or immediate family members&#xD;
             of site or sponsor employees.&#xD;
&#xD;
          3. Subjects who have previously been administered IMP in this study. Subjects who have&#xD;
             taken part in one part of this study are not permitted to take part in any other study&#xD;
             part.&#xD;
&#xD;
          4. History of any drug or alcohol abuse in the past 2 years.&#xD;
&#xD;
          5. Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week&#xD;
             (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of&#xD;
             wine, depending on type).&#xD;
&#xD;
          6. A confirmed positive alcohol breath test at screening or admission.&#xD;
&#xD;
          7. Current smokers and those who have smoked within the last 12 months. A confirmed&#xD;
             breath carbon monoxide reading of greater than 10 ppm at screening or admission.&#xD;
&#xD;
          8. Current users of e-cigarettes and nicotine replacement products and those who have&#xD;
             used these products within the last 12 months.&#xD;
&#xD;
          9. Females of childbearing potential who are pregnant or lactating (all female subjects&#xD;
             must have a negative serum pregnancy test at screening and urine pregnancy test on&#xD;
             admission).&#xD;
&#xD;
         10. Subjects with pregnant or lactating partners.&#xD;
&#xD;
         11. Subjects who do not have suitable veins for multiple venepunctures/cannulation as&#xD;
             assessed by the investigator or delegate at screening.&#xD;
&#xD;
         12. Clinically significant abnormal clinical chemistry, haematology, coagulation or&#xD;
             urinalysis as judged by the investigator. Subjects with Gilbert's Syndrome are&#xD;
             allowed.&#xD;
&#xD;
         13. Confirmed positive drugs of abuse test result.&#xD;
&#xD;
         14. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) antibody results.&#xD;
&#xD;
         15. Evidence of renal impairment at screening, as indicated by an estimated creatinine&#xD;
             clearance of &lt;70 mL/min using the Cockcroft-Gault equation.&#xD;
&#xD;
         16. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory&#xD;
             or gastrointestinal disease, neurological or psychiatric disorder, as judged by the&#xD;
             investigator.&#xD;
&#xD;
         17. Subjects with a history of cholecystectomy or gall stones.&#xD;
&#xD;
         18. Serious adverse reaction or serious hypersensitivity to any drug or the formulation&#xD;
             excipients.&#xD;
&#xD;
         19. Presence or history of clinically significant allergy requiring treatment, as judged&#xD;
             by the investigator. Hay fever is allowed unless it is active.&#xD;
&#xD;
         20. Donation or loss of greater than 400 mL of blood within the previous 3 months.&#xD;
&#xD;
         21. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or&#xD;
             herbal remedies (other than up to 4 g of paracetamol per day, HRT or hormonal&#xD;
             contraception) in the 14 days before IMP administration.&#xD;
&#xD;
         22. Failure to satisfy the investigator of fitness to participate for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

